PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 59 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $586,276 | -18.5% | 56,537 | +12.6% | 0.00% | 0.0% |
Q2 2023 | $718,935 | +307137.2% | 50,205 | +53.2% | 0.00% | – |
Q1 2023 | $234 | -32.2% | 32,761 | +6.6% | 0.00% | – |
Q4 2022 | $345 | -99.9% | 30,732 | +6.2% | 0.00% | – |
Q3 2022 | $321,000 | +42.7% | 28,927 | +8.5% | 0.00% | – |
Q2 2022 | $225,000 | -17.3% | 26,649 | +33.5% | 0.00% | – |
Q1 2022 | $272,000 | -19.5% | 19,968 | +16.0% | 0.00% | – |
Q4 2021 | $338,000 | -39.6% | 17,207 | -1.4% | 0.00% | -100.0% |
Q3 2021 | $560,000 | +0.7% | 17,454 | +6.2% | 0.00% | 0.0% |
Q2 2021 | $556,000 | +29.9% | 16,438 | +44.3% | 0.00% | 0.0% |
Q1 2021 | $428,000 | +5.7% | 11,390 | -6.6% | 0.00% | 0.0% |
Q4 2020 | $405,000 | +1.2% | 12,200 | +11.7% | 0.00% | 0.0% |
Q3 2020 | $400,000 | -5.0% | 10,920 | -14.6% | 0.00% | 0.0% |
Q2 2020 | $421,000 | +42.7% | 12,790 | +12.0% | 0.00% | 0.0% |
Q1 2020 | $295,000 | +35.3% | 11,423 | +63.5% | 0.00% | – |
Q4 2019 | $218,000 | – | 6,986 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |